Guggenheim Remains Bullish Ahead of Teva Pharma's (TEVA) AGN Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Leerink Highlights Top 10 Biopharma Stocks for Partnerships & Acquisitions
April 14, 2016 12:07 PM EDTIn addition to naming Acadia Pharma (NASDAQ: ACAD) one of his top partnership and acquisition (P&A) targets, as noted earlier, Leerink analyst Joseph Schwartz listed 9 other stocks on his Top 10 list. Below is a run-down of the others:
Akorn, Inc. (NASDAQ: AKRX) (Market Perform)
Rationale for P&A: "AKRX operates in generic segments with higher barriers... More
Acadia Pharma (ACAD) Higher as Leerink Highlights as Partnership and Acquisition Target
April 14, 2016 9:57 AM EDTAcadia Pharma (NASDAQ: ACAD) is solidly higher early Thursday (+3.2%) after Leerink Partners analyst Joseph Schwartz highlighted the company as one his Top Ten partnership and acquisition (P&A) stocks in biophama.
Commenting on the rationale for P&A, he said:
"Recent positive... More
